^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAEST16001

    i
    Company:
    Athenex, Guangzhou Xiangxue Pharma
    Drug class:
    TCR modulator, NY ESO 1 inhibitor
    Related drugs:
    Apply
    Phase II Study of TAEST16001 in Soft Tissue Sarcoma (NCT05549921)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    12/27/2023
    Initiation :
    07/08/2022
    Primary completion :
    09/01/2024
    Completion :
    09/01/2024
    HLA-A • CTAG1B
    |
    HLA-A*02:01 • HLA-A*02
    |
    TAEST16001
    NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma (NCT03462316)
    Phase 1
    Sun Yat-sen University
    Active, not recruiting
    Last update posted :
    04/12/2023
    Initiation :
    05/21/2018
    Primary completion :
    02/15/2024
    Completion :
    05/15/2024
    CTAG1B
    |
    cyclophosphamide • TAEST16001
    TAEST16001 in the Treatment of Soft Tissue Sarcoma (NCT04318964)
    Phase 1
    Sun Yat-sen University
    Active, not recruiting
    Last update posted :
    04/12/2023
    Initiation :
    03/19/2020
    Primary completion :
    04/15/2022
    Completion :
    05/01/2024
    IL6 • CTAG1B
    |
    TAEST16001
    To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors (NCT03159585)
    Phase 1
    Zhujiang Hospital
    Completed
    Last update posted :
    01/22/2020
    Initiation :
    04/14/2017
    Primary completion :
    06/04/2019
    Completion :
    06/04/2019
    CTAG1B
    |
    cyclophosphamide • TAEST16001
    NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC (NCT03029273)
    Phase 1
    Guangzhou Institute of Respiratory Disease
    Unknown status
    Last update posted :
    01/17/2019
    Initiation :
    03/21/2017
    Primary completion :
    03/01/2019
    Completion :
    03/01/2019
    EGFR • ALK • CTAG1B
    |
    EGFR mutation • ALK rearrangement • CTAG1B expression
    |
    cyclophosphamide • fludarabine IV • TAEST16001 • cyclophosphamide intravenous